keyword
MENU ▼
Read by QxMD icon Read
search

Reecha sofat

keyword
https://www.readbyqxmd.com/read/28783690/cross-talk-between-inkt-cells-and-monocytes-triggers-an-atheroprotective-immune-response-in-sle-patients-with-asymptomatic-plaque
#1
Edward Smith, Sara Croca, Kirsty E Waddington, Reecha Sofat, Maura Griffin, Andrew Nicolaides, David A Isenberg, Ines Pineda Torra, Anisur Rahman, Elizabeth C Jury
Accelerated atherosclerosis is a complication of the autoimmune rheumatic disease systemic lupus erythematosus (SLE). We questioned the role played by invariant natural killer T (iNKT) cells in this process because they not only are defective in autoimmunity but also promote atherosclerosis in response to CD1d-mediated lipid antigen presentation. iNKT cells from SLE patients with asymptomatic plaque (SLE-P) had increased proliferation and interleukin-4 production compared with those from SLE patients with no plaque...
December 2, 2016: Science Immunology
https://www.readbyqxmd.com/read/28750115/association-of-c-reactive-protein-genetic-polymorphisms-with-late-age-related-macular-degeneration
#2
Valentina Cipriani, Ruth E Hogg, Reecha Sofat, Anthony T Moore, Andrew R Webster, John R W Yates, Astrid E Fletcher
Importance: C-reactive protein (CRP) is a circulating inflammatory marker associated with late age-related macular degeneration (AMD). It remains uncertain whether the association between CRP concentrations and AMD is causal. Objective: To assess whether CRP (OMIM 123260) single-nucleotide polymorphisms that influence circulating CRP concentrations are associated with late AMD. Design, Setting, and Participants: Participants in 2 UK, hospital-based, case-control studies (Cambridge AMD study and Moorfields Eye Hospital AMD study) and 1 pan-European, cross-sectional, population-based study (the European Eye [EUREYE] Study) were recruited between November 6, 2000, and April 30, 2007...
September 1, 2017: JAMA Ophthalmology
https://www.readbyqxmd.com/read/28629510/screening-strategies-for-atrial-fibrillation-a-systematic-review-and-cost-effectiveness-analysis
#3
Nicky J Welton, Alexandra McAleenan, Howard Hz Thom, Philippa Davies, Will Hollingworth, Julian Pt Higgins, George Okoli, Jonathan Ac Sterne, Gene Feder, Diane Eaton, Aroon Hingorani, Christopher Fawsitt, Trudie Lobban, Peter Bryden, Alison Richards, Reecha Sofat
BACKGROUND: Atrial fibrillation (AF) is a common cardiac arrhythmia that increases the risk of thromboembolic events. Anticoagulation therapy to prevent AF-related stroke has been shown to be cost-effective. A national screening programme for AF may prevent AF-related events, but would involve a substantial investment of NHS resources. OBJECTIVES: To conduct a systematic review of the diagnostic test accuracy (DTA) of screening tests for AF, update a systematic review of comparative studies evaluating screening strategies for AF, develop an economic model to compare the cost-effectiveness of different screening strategies and review observational studies of AF screening to provide inputs to the model...
May 2017: Health Technology Assessment: HTA
https://www.readbyqxmd.com/read/28500271/causal-associations-of-adiposity-and-body-fat-distribution-with-coronary-heart-disease-stroke-subtypes-and-type-2-diabetes-mellitus-a-mendelian-randomization-analysis
#4
Caroline E Dale, Ghazaleh Fatemifar, Tom M Palmer, Jon White, David Prieto-Merino, Delilah Zabaneh, Jorgen E L Engmann, Tina Shah, Andrew Wong, Helen R Warren, Stela McLachlan, Stella Trompet, Max Moldovan, Richard W Morris, Reecha Sofat, Meena Kumari, Elina Hyppönen, Barbara J Jefferis, Tom R Gaunt, Yoav Ben-Shlomo, Ang Zhou, Aleksandra Gentry-Maharaj, Andy Ryan, Renée de Mutsert, Raymond Noordam, Mark J Caulfield, J Wouter Jukema, Bradford B Worrall, Patricia B Munroe, Usha Menon, Chris Power, Diana Kuh, Debbie A Lawlor, Steve E Humphries, Dennis O Mook-Kanamori, Naveed Sattar, Mika Kivimaki, Jacqueline F Price, George Davey Smith, Frank Dudbridge, Aroon D Hingorani, Michael V Holmes, Juan P Casas
BACKGROUND: The implications of different adiposity measures on cardiovascular disease etiology remain unclear. In this article, we quantify and contrast causal associations of central adiposity (waist-to-hip ratio adjusted for body mass index [WHRadjBMI]) and general adiposity (body mass index [BMI]) with cardiometabolic disease. METHODS: Ninety-seven independent single-nucleotide polymorphisms for BMI and 49 single-nucleotide polymorphisms for WHRadjBMI were used to conduct Mendelian randomization analyses in 14 prospective studies supplemented with coronary heart disease (CHD) data from CARDIoGRAMplusC4D (Coronary Artery Disease Genome-wide Replication and Meta-analysis [CARDIoGRAM] plus The Coronary Artery Disease [C4D] Genetics; combined total 66 842 cases), stroke from METASTROKE (12 389 ischemic stroke cases), type 2 diabetes mellitus from DIAGRAM (Diabetes Genetics Replication and Meta-analysis; 34 840 cases), and lipids from GLGC (Global Lipids Genetic Consortium; 213 500 participants) consortia...
June 13, 2017: Circulation
https://www.readbyqxmd.com/read/28279251/oral-anticoagulants-for-primary-prevention-treatment-and-secondary-prevention-of-venous-thromboembolic-disease-and-for-prevention-of-stroke-in-atrial-fibrillation-systematic-review-network-meta-analysis-and-cost-effectiveness-analysis
#5
Jonathan Ac Sterne, Pritesh N Bodalia, Peter A Bryden, Philippa A Davies, Jose A López-López, George N Okoli, Howard Hz Thom, Deborah M Caldwell, Sofia Dias, Diane Eaton, Julian Pt Higgins, Will Hollingworth, Chris Salisbury, Jelena Savović, Reecha Sofat, Annya Stephens-Boal, Nicky J Welton, Aroon D Hingorani
BACKGROUND: Warfarin is effective for stroke prevention in atrial fibrillation (AF), but anticoagulation is underused in clinical care. The risk of venous thromboembolic disease during hospitalisation can be reduced by low-molecular-weight heparin (LMWH): warfarin is the most frequently prescribed anticoagulant for treatment and secondary prevention of venous thromboembolism (VTE). Warfarin-related bleeding is a major reason for hospitalisation for adverse drug effects. Warfarin is cheap but therapeutic monitoring increases treatment costs...
March 2017: Health Technology Assessment: HTA
https://www.readbyqxmd.com/read/27755538/circulating-apolipoprotein-e-concentration-and-cardiovascular-disease-risk-meta-analysis-of-results-from-three-studies
#6
Reecha Sofat, Jackie A Cooper, Meena Kumari, Juan P Casas, Jacqueline P Mitchell, Jayshree Acharya, Simon Thom, Alun D Hughes, Steve E Humphries, Aroon D Hingorani
BACKGROUND: The association of APOE genotype with circulating apolipoprotein E (ApoE) concentration and cardiovascular disease (CVD) risk is well established. However, the relationship of circulating ApoE concentration and CVD has received little attention. METHODS AND FINDINGS: To address this, we measured circulating ApoE concentration in 9,587 individuals (with 1,413 CVD events) from three studies with incident CVD events: two population-based studies, the English Longitudinal Study of Ageing (ELSA) and the men-only Northwick Park Heart Study II (NPHSII), and a nested sub-study of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)...
October 2016: PLoS Medicine
https://www.readbyqxmd.com/read/27342221/selecting-instruments-for-mendelian-randomization-in-the-wake-of-genome-wide-association-studies
#7
Daniel I Swerdlow, Karoline B Kuchenbaecker, Sonia Shah, Reecha Sofat, Michael V Holmes, Jon White, Jennifer S Mindell, Mika Kivimaki, Eric J Brunner, John C Whittaker, Juan P Casas, Aroon D Hingorani
Mendelian randomization (MR) studies typically assess the pathogenic relevance of environmental exposures or disease biomarkers, using genetic variants that instrument these exposures. The approach is gaining popularity-our systematic review reveals a greater than 10-fold increase in MR studies published between 2004 and 2015. When the MR paradigm was first proposed, few biomarker- or exposure-related genetic variants were known, most having been identified by candidate gene studies. However, genome-wide association studies (GWAS) are now providing a rich source of potential instruments for MR analysis...
October 2016: International Journal of Epidemiology
https://www.readbyqxmd.com/read/26781229/plasma-urate-concentration-and-risk-of-coronary-heart-disease-a-mendelian-randomisation-analysis
#8
Jon White, Reecha Sofat, Gibran Hemani, Tina Shah, Jorgen Engmann, Caroline Dale, Sonia Shah, Felix A Kruger, Claudia Giambartolomei, Daniel I Swerdlow, Tom Palmer, Stela McLachlan, Claudia Langenberg, Delilah Zabaneh, Ruth Lovering, Alana Cavadino, Barbara Jefferis, Chris Finan, Andrew Wong, Antoinette Amuzu, Ken Ong, Tom R Gaunt, Helen Warren, Teri-Louise Davies, Fotios Drenos, Jackie Cooper, Shah Ebrahim, Debbie A Lawlor, Philippa J Talmud, Steve E Humphries, Christine Power, Elina Hypponen, Marcus Richards, Rebecca Hardy, Diana Kuh, Nicholas Wareham, Yoav Ben-Shlomo, Ian N Day, Peter Whincup, Richard Morris, Mark W J Strachan, Jacqueline Price, Meena Kumari, Mika Kivimaki, Vincent Plagnol, John C Whittaker, George Davey Smith, Frank Dudbridge, Juan P Casas, Michael V Holmes, Aroon D Hingorani
BACKGROUND: Increased circulating plasma urate concentration is associated with an increased risk of coronary heart disease, but the extent of any causative effect of urate on risk of coronary heart disease is still unclear. In this study, we aimed to clarify any causal role of urate on coronary heart disease risk using Mendelian randomisation analysis. METHODS: We first did a fixed-effects meta-analysis of the observational association of plasma urate and risk of coronary heart disease...
April 2016: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/25262344/hmg-coenzyme-a-reductase-inhibition-type-2-diabetes-and-bodyweight-evidence-from-genetic-analysis-and-randomised-trials
#9
Daniel I Swerdlow, David Preiss, Karoline B Kuchenbaecker, Michael V Holmes, Jorgen E L Engmann, Tina Shah, Reecha Sofat, Stefan Stender, Paul C D Johnson, Robert A Scott, Maarten Leusink, Niek Verweij, Stephen J Sharp, Yiran Guo, Claudia Giambartolomei, Christina Chung, Anne Peasey, Antoinette Amuzu, KaWah Li, Jutta Palmen, Philip Howard, Jackie A Cooper, Fotios Drenos, Yun R Li, Gordon Lowe, John Gallacher, Marlene C W Stewart, Ioanna Tzoulaki, Sarah G Buxbaum, Daphne L van der A, Nita G Forouhi, N Charlotte Onland-Moret, Yvonne T van der Schouw, Renate B Schnabel, Jaroslav A Hubacek, Ruzena Kubinova, Migle Baceviciene, Abdonas Tamosiunas, Andrzej Pajak, Roman Topor-Madry, Urszula Stepaniak, Sofia Malyutina, Damiano Baldassarre, Bengt Sennblad, Elena Tremoli, Ulf de Faire, Fabrizio Veglia, Ian Ford, J Wouter Jukema, Rudi G J Westendorp, Gert Jan de Borst, Pim A de Jong, Ale Algra, Wilko Spiering, Anke H Maitland-van der Zee, Olaf H Klungel, Anthonius de Boer, Pieter A Doevendans, Charles B Eaton, Jennifer G Robinson, David Duggan, John Kjekshus, John R Downs, Antonio M Gotto, Anthony C Keech, Roberto Marchioli, Gianni Tognoni, Peter S Sever, Neil R Poulter, David D Waters, Terje R Pedersen, Pierre Amarenco, Haruo Nakamura, John J V McMurray, James D Lewsey, Daniel I Chasman, Paul M Ridker, Aldo P Maggioni, Luigi Tavazzi, Kausik K Ray, Sreenivasa Rao Kondapally Seshasai, JoAnn E Manson, Jackie F Price, Peter H Whincup, Richard W Morris, Debbie A Lawlor, George Davey Smith, Yoav Ben-Shlomo, Pamela J Schreiner, Myriam Fornage, David S Siscovick, Mary Cushman, Meena Kumari, Nick J Wareham, W M Monique Verschuren, Susan Redline, Sanjay R Patel, John C Whittaker, Anders Hamsten, Joseph A Delaney, Caroline Dale, Tom R Gaunt, Andrew Wong, Diana Kuh, Rebecca Hardy, Sekar Kathiresan, Berta A Castillo, Pim van der Harst, Eric J Brunner, Anne Tybjaerg-Hansen, Michael G Marmot, Ronald M Krauss, Michael Tsai, Josef Coresh, Ronald C Hoogeveen, Bruce M Psaty, Leslie A Lange, Hakon Hakonarson, Frank Dudbridge, Steve E Humphries, Philippa J Talmud, Mika Kivimäki, Nicholas J Timpson, Claudia Langenberg, Folkert W Asselbergs, Mikhail Voevoda, Martin Bobak, Hynek Pikhart, James G Wilson, Alex P Reiner, Brendan J Keating, Aroon D Hingorani, Naveed Sattar
BACKGROUND: Statins increase the risk of new-onset type 2 diabetes mellitus. We aimed to assess whether this increase in risk is a consequence of inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), the intended drug target. METHODS: We used single nucleotide polymorphisms in the HMGCR gene, rs17238484 (for the main analysis) and rs12916 (for a subsidiary analysis) as proxies for HMGCR inhibition by statins. We examined associations of these variants with plasma lipid, glucose, and insulin concentrations; bodyweight; waist circumference; and prevalent and incident type 2 diabetes...
January 24, 2015: Lancet
https://www.readbyqxmd.com/read/24563418/novel-genetic-approach-to-investigate-the-role-of-plasma-secretory-phospholipase-a2-spla2-v-isoenzyme-in-coronary-heart-disease-modified-mendelian-randomization-analysis-using-pla2g5-expression-levels
#10
Michael V Holmes, Holly J Exeter, Lasse Folkersen, Christopher P Nelson, Montse Guardiola, Jackie A Cooper, Reecha Sofat, S Matthijs Boekholdt, Kay-Tee Khaw, Ka-Wah Li, Andrew J P Smith, Ferdinand Van't Hooft, Per Eriksson, Anders Franco-Cereceda, Folkert W Asselbergs, Jolanda M A Boer, N Charlotte Onland-Moret, Marten Hofker, Jeanette Erdmann, Mika Kivimaki, Meena Kumari, Alex P Reiner, Brendan J Keating, Steve E Humphries, Aroon D Hingorani, Ziad Mallat, Nilesh J Samani, Philippa J Talmud
BACKGROUND: Secretory phospholipase A2 (sPLA2) enzymes are considered to play a role in atherosclerosis. sPLA2 activity encompasses several sPLA2 isoenzymes, including sPLA2-V. Although observational studies show a strong association between elevated sPLA2 activity and CHD, no assay to measure sPLA2-V levels exists, and the only evidence linking the sPLA2-V isoform to atherosclerosis progression comes from animal studies. In the absence of an assay that directly quantifies sPLA2-V levels, we used PLA2G5 mRNA levels in a novel, modified Mendelian randomization approach to investigate the hypothesized causal role of sPLA2-V in coronary heart disease (CHD) pathogenesis...
April 2014: Circulation. Cardiovascular Genetics
https://www.readbyqxmd.com/read/24474739/mendelian-randomization-of-blood-lipids-for-coronary-heart-disease
#11
Michael V Holmes, Folkert W Asselbergs, Tom M Palmer, Fotios Drenos, Matthew B Lanktree, Christopher P Nelson, Caroline E Dale, Sandosh Padmanabhan, Chris Finan, Daniel I Swerdlow, Vinicius Tragante, Erik P A van Iperen, Suthesh Sivapalaratnam, Sonia Shah, Clara C Elbers, Tina Shah, Jorgen Engmann, Claudia Giambartolomei, Jon White, Delilah Zabaneh, Reecha Sofat, Stela McLachlan, Pieter A Doevendans, Anthony J Balmforth, Alistair S Hall, Kari E North, Berta Almoguera, Ron C Hoogeveen, Mary Cushman, Myriam Fornage, Sanjay R Patel, Susan Redline, David S Siscovick, Michael Y Tsai, Konrad J Karczewski, Marten H Hofker, W Monique Verschuren, Michiel L Bots, Yvonne T van der Schouw, Olle Melander, Anna F Dominiczak, Richard Morris, Yoav Ben-Shlomo, Jackie Price, Meena Kumari, Jens Baumert, Annette Peters, Barbara Thorand, Wolfgang Koenig, Tom R Gaunt, Steve E Humphries, Robert Clarke, Hugh Watkins, Martin Farrall, James G Wilson, Stephen S Rich, Paul I W de Bakker, Leslie A Lange, George Davey Smith, Alex P Reiner, Philippa J Talmud, Mika Kivimäki, Debbie A Lawlor, Frank Dudbridge, Nilesh J Samani, Brendan J Keating, Aroon D Hingorani, Juan P Casas
AIMS: To investigate the causal role of high-density lipoprotein cholesterol (HDL-C) and triglycerides in coronary heart disease (CHD) using multiple instrumental variables for Mendelian randomization. METHODS AND RESULTS: We developed weighted allele scores based on single nucleotide polymorphisms (SNPs) with established associations with HDL-C, triglycerides, and low-density lipoprotein cholesterol (LDL-C). For each trait, we constructed two scores. The first was unrestricted, including all independent SNPs associated with the lipid trait identified from a prior meta-analysis (threshold P < 2 × 10(-6)); and the second a restricted score, filtered to remove any SNPs also associated with either of the other two lipid traits at P ≤ 0...
March 1, 2015: European Heart Journal
https://www.readbyqxmd.com/read/23977022/population-genomics-of-cardiometabolic-traits-design-of-the-university-college-london-london-school-of-hygiene-and-tropical-medicine-edinburgh-bristol-ucleb-consortium
#12
Tina Shah, Jorgen Engmann, Caroline Dale, Sonia Shah, Jon White, Claudia Giambartolomei, Stela McLachlan, Delilah Zabaneh, Alana Cavadino, Chris Finan, Andrew Wong, Antoinette Amuzu, Ken Ong, Tom Gaunt, Michael V Holmes, Helen Warren, Daniel I Swerdlow, Teri-Louise Davies, Fotios Drenos, Jackie Cooper, Reecha Sofat, Mark Caulfield, Shah Ebrahim, Debbie A Lawlor, Philippa J Talmud, Steve E Humphries, Christine Power, Elina Hypponen, Marcus Richards, Rebecca Hardy, Diana Kuh, Nicholas Wareham, Claudia Langenberg, Yoav Ben-Shlomo, Ian N Day, Peter Whincup, Richard Morris, Mark W J Strachan, Jacqueline Price, Meena Kumari, Mika Kivimaki, Vincent Plagnol, Frank Dudbridge, John C Whittaker, Juan P Casas, Aroon D Hingorani
Substantial advances have been made in identifying common genetic variants influencing cardiometabolic traits and disease outcomes through genome wide association studies. Nevertheless, gaps in knowledge remain and new questions have arisen regarding the population relevance, mechanisms, and applications for healthcare. Using a new high-resolution custom single nucleotide polymorphism (SNP) array (Metabochip) incorporating dense coverage of genomic regions linked to cardiometabolic disease, the University College-London School-Edinburgh-Bristol (UCLEB) consortium of highly-phenotyped population-based prospective studies, aims to: (1) fine map functionally relevant SNPs; (2) precisely estimate individual absolute and population attributable risks based on individual SNPs and their combination; (3) investigate mechanisms leading to altered risk factor profiles and CVD events; and (4) use Mendelian randomisation to undertake studies of the causal role in CVD of a range of cardiovascular biomarkers to inform public health policy and help develop new preventative therapies...
2013: PloS One
https://www.readbyqxmd.com/read/23733552/genetic-risk-factors-for-intracranial-aneurysms-a-meta-analysis-in-more-than-116-000-individuals
#13
REVIEW
Varinder S Alg, Reecha Sofat, Henry Houlden, David J Werring
OBJECTIVE: There is an urgent need to identify risk factors for sporadic intracranial aneurysm (IA) development and rupture. A genetic component has long been recognized, but firm conclusions have been elusive given the generally small sample sizes and lack of replication. Genome-wide association studies have overcome some limitations, but the number of robust genetic risk factors for IA remains uncertain. METHODS: We conducted a comprehensive systematic review and meta-analysis of all genetic association studies (including genome-wide association studies) of sporadic IA, conducted according to Strengthening the Reporting of Genetic Association Studies and Human Genome Epidemiology Network guidelines...
June 4, 2013: Neurology
https://www.readbyqxmd.com/read/23505291/gene-centric-analysis-identifies-variants-associated-with-interleukin-6-levels-and-shared-pathways-with-other-inflammation-markers
#14
Tina Shah, Delilah Zabaneh, Tom Gaunt, Daniel I Swerdlow, Sonia Shah, Philippa J Talmud, Ian N Day, John Whittaker, Michael V Holmes, Reecha Sofat, Steve E Humphries, Mika Kivimaki, Meena Kumari, Aroon D Hingorani, Juan P Casas
BACKGROUND- Inflammatory cytokine interleukin-6 (IL-6), a possible risk factor for coronary heart disease, has an estimated heritability of >60%, but to date few genetic variants influencing IL-6 levels are known. METHODS AND RESULTS- We used the ITMAT-Broad-Care (IBC) HumanCVD disease BeadChip in the Whitehall II study (N=4911) and British Women's Heart and Health Study (N=3445) to identify single-nucleotide polymorphisms associated with circulating IL-6 levels. Twenty-two single-nucleotide polymorphisms from 7 loci (IL6R/TDRD10, HLA-DRB1, BUD13, SEZ6L, IL1RN, TRIB3, and ABO) were associated with IL-6 (P<10(-5)), although none were associated with the IL6 gene itself...
April 2013: Circulation. Cardiovascular Genetics
https://www.readbyqxmd.com/read/23376722/distribution-and-determinants-of-circulating-complement-factor-h-concentration-determined-by-a-high-throughput-immunonephelometric-assay
#15
Reecha Sofat, P Patrizia Mangione, J Ruth Gallimore, Svetlana Hakobyan, Timothy R Hughes, Tina Shah, Tim Goodship, Francesco D'Aiuto, Claudia Langenberg, Nick Wareham, B Paul Morgan, Mark B Pepys, Aroon D Hingorani
BACKGROUND: Research on complement factor H (fH) in human disease is hampered by lack of an assay suitable for use in large-scale epidemiological studies. We describe the development and validation of a high throughput nephelometric assay for fH. METHODS: Reagents from a commercial radial immunodiffusion (RID) assay (The Binding Site) were adapted for use on the Siemens BNII high throughput nephelometric instrument. The assay was calibrated with a highly purified human fH preparation with rigorously determined concentration, and assay performance was comprehensively evaluated using samples from healthy human volunteers, with the commercial RID assay as a comparator...
April 30, 2013: Journal of Immunological Methods
https://www.readbyqxmd.com/read/23351090/comparative-efficacy-and-tolerability-of-anti-epileptic-drugs-for-refractory-focal-epilepsy-systematic-review-and-network-meta-analysis-reveals-the-need-for-long-term-comparator-trials
#16
REVIEW
Pritesh N Bodalia, Anthony M Grosso, Reecha Sofat, Raymond J Macallister, Liam Smeeth, Soraya Dhillon, Juan-Pablo Casas, David Wonderling, Aroon D Hingorani
AIMS: To evaluate the comparative efficacy (50% reduction in seizure frequency) and tolerability (premature withdrawal due to adverse events) of anti-epileptic drugs (AEDs) for refractory epilepsy. METHODS: We searched Cochrane Central Register of Controlled Trials (Cochrane Library 2009, issue 2) including Epilepsy Group's specialized register, MEDLINE (1950 to March 2009), EMBASE (1980 to March 2009), and Current Contents Connect (1998 to March 2009) to conduct a systematic review of published studies, developed a treatment network and undertook a network meta-analysis...
November 2013: British Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/23098369/arms2-increases-the-risk-of-early-and-late-age-related-macular-degeneration-in-the-european-eye-study
#17
MULTICENTER STUDY
Usha Chakravarthy, Gareth J McKay, Paulus T V M de Jong, Mati Rahu, Johan Seland, Gisele Soubrane, Laura Tomazzoli, Fotis Topouzis, Johannes R Vingerling, Jesus Vioque, Ian S Young, Reecha Sofat, Aroon D Hingorani, Astrid E Fletcher
OBJECTIVE: To study associations between severity stages of early and late age-related macular degeneration (AMD) and genetic variations in age-related maculopathy susceptibility 2 (ARMS2) and complement factor H (CFH) and to investigate potential interactions between smoking and ARMS2. DESIGN: Population-based, cross-sectional European Eye Study in 7 countries in Europe. PARTICIPANTS: Four thousand seven hundred fifty participants, 65 years of age and older, recruited through random sampling...
February 2013: Ophthalmology
https://www.readbyqxmd.com/read/22977227/influence-of-common-genetic-variation-on-blood-lipid-levels-cardiovascular-risk-and-coronary-events-in-two-british-prospective-cohort-studies
#18
Sonia Shah, Juan P Casas, Tom R Gaunt, Jackie Cooper, Fotios Drenos, Delilah Zabaneh, Daniel I Swerdlow, Tina Shah, Reecha Sofat, Jutta Palmen, Meena Kumari, Mika Kivimaki, Shah Ebrahim, George Davey Smith, Debbie A Lawlor, Philippa J Talmud, John Whittaker, Ian N M Day, Aroon D Hingorani, Steve E Humphries
AIMS: The aim of this study was to quantify the collective effect of common lipid-associated single nucleotide polymorphisms (SNPs) on blood lipid levels, cardiovascular risk, use of lipid-lowering medication, and risk of coronary heart disease (CHD) events. METHODS AND RESULTS: Analysis was performed in two prospective cohorts: Whitehall II (WHII; N = 5059) and the British Women's Heart and Health Study (BWHHS; N = 3414). For each participant, scores were calculated based on the cumulative effect of multiple genetic variants influencing total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides (TG)...
April 2013: European Heart Journal
https://www.readbyqxmd.com/read/22766581/is-it-important-to-measure-or-reduce-c-reactive-protein-in-people-at-risk-of-cardiovascular-disease
#19
Aroon D Hingorani, Reecha Sofat, Richard W Morris, Peter Whincup, Gordon D Lowe, Jennifer Mindell, Naveed Sattar, Juan P Casas, Tina Shah
No abstract text is available yet for this article.
September 2012: European Heart Journal
https://www.readbyqxmd.com/read/22253316/complement-factor-h-genetic-variant-and-age-related-macular-degeneration-effect-size-modifiers-and-relationship-to-disease-subtype
#20
Reecha Sofat, Juan P Casas, Andrew R Webster, Alan C Bird, Samantha S Mann, John R W Yates, Anthony T Moore, Tiina Sepp, Valentina Cipriani, Catey Bunce, Jane C Khan, Humma Shahid, Anand Swaroop, Gonçalo Abecasis, Kari E H Branham, Sepideh Zareparsi, Arthur A Bergen, Caroline C W Klaver, Dominique C Baas, Kang Zhang, Yuhong Chen, Daniel Gibbs, Bernhard H F Weber, Claudia N Keilhauer, Lars G Fritsche, Andrew Lotery, Angela J Cree, Helen L Griffiths, Shomi S Bhattacharya, Li L Chen, Sharon A Jenkins, Tunde Peto, Mark Lathrop, Thierry Leveillard, Michael B Gorin, Daniel E Weeks, Maria Carolina Ortube, Robert E Ferrell, Johanna Jakobsdottir, Yvette P Conley, Mati Rahu, Johan H Seland, Gisele Soubrane, Fotis Topouzis, Jesus Vioque, Laura Tomazzoli, Ian Young, John Whittaker, Usha Chakravarthy, Paulus T V M de Jong, Liam Smeeth, Astrid Fletcher, Aroon D Hingorani
BACKGROUND: Variation in the complement factor H gene (CFH) is associated with risk of late age-related macular degeneration (AMD). Previous studies have been case-control studies in populations of European ancestry with little differentiation in AMD subtype, and insufficient power to confirm or refute effect modification by smoking. METHODS: To precisely quantify the association of the single nucleotide polymorphism (SNP rs1061170, 'Y402H') with risk of AMD among studies with differing study designs, participant ancestry and AMD grade and to investigate effect modification by smoking, we report two unpublished genetic association studies (n = 2759) combined with data from 24 published studies (26 studies, 26,494 individuals, including 14,174 cases of AMD) of European ancestry, 10 of which provided individual-level data used to test gene-smoking interaction; and 16 published studies from non-European ancestry...
February 2012: International Journal of Epidemiology
keyword
keyword
108100
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"